Please find enclosed investor presentation.

27th October, 2026 (1) BSE Limited (2) National Stock Exchange of India Limited Listing Department Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th floor, Dalal Street, Plot no. C/1, G Block, Bandra Kurla Complex, Mumbai - 400 001 Bandra (East), Mumbai - 400 051 Scrip Code: 500087 Scrip Symbol: CIPLA (3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg Sub: Investor Presentation – Q2FY27 Financial Results Dear Sir / Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Investor Presentation for Q2FY27 Financial Results dated 27th October, 2026. Kindly take the above information on record. Thanking you, Yours faithfully, For Cipla Limited Rajendra Chopra Company Secretary Encl: As above Prepared by: Simona Dsouza Cipla Ltd. Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India P +91 22 41916000 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380 Investor Presentation Q2FY27 27-10-2026 DISCLAIMER Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties, pandemic and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks. The investor presentation is not intended to endorse, advertise, promote or recommend the use of any products listed in it which are for representation purpose only, some of which are reference listed drugs of which the Company has approved, under approval or under development generic equivalents. The prefixes “g” and “generic” used interchangeably indicate the generic versions of the named brand drugs. Information relating to any medical products or medical devices contained herein is provided by Cipla for general information purposes only. Information on any of the medical products or medical devices may vary from country-to-country. A reference to a medical product or a medical device does not imply that such medical product or medical device is available in your country. The commercial availability of the medical products or medical devices listed herein in your country is dependent on the validity and status of existing patents and/or marketing authorizations related to each. An independent enquiry regarding the availability of each medical products or medical device should be made for each individual country. The product information contained herein is not intended to provide complete medical information, and is not intended to be used as an alternative to consulting with qualified doctors or health care professionals. Nothing contained herein should be construed as giving of advice or the making of a recommendation and it should not be relied on as the basis for any decision or action. It is important to only rely on the advice of a health care professional. Consistent Sequential Growth in Revenue and EBITDA Reflecting Sustained Business Momentum Revenue EBITDA PAT 18.7% 11.9% Q2FY27 INR 7,404 Cr INR 1,388 Cr INR 878 Cr Margin Margin Business Performance Snapshot Emerging Markets & One India North America One Africa Europe INR 3,516 Cr $ 172 Mn $ 123 Mn $ 101 Mn (YoY) Q2FY27 Highest-ever quarterly Received U.S. FDA approval SA private growing 1.3x faster Resilient performance amid revenue for gAdvair Diskus than the market1 geopolitical uncertainties 1. Market data as per IQVIA MAT Aug’26 Financial Performance : Q2FY27 Revenues INR 7,404 Cr EBITDA 1,388 Cr Revenue1 Break-up Q2FY27 (Consolidated) API and Q2FY27 Q2FY26 Others, 1% (INR Cr) (INR Cr) Emerging Total Revenue from markets and 7,404 7,589 Europe, 13% Operations EBITDA 1,388 1,895 One Africa, EBITDA % 18.7% 25.0% 16% One India, 48% PAT 878 1,351 PAT % 11.9% 17.8.% R&D2 INR 423 Cr | 5.7% of revenue North America, 22% 1. One India includes Rx + Gx + CHL; One Africa includes South Africa, North Africa, Sub-Saharan Africa (SSA) and Cipla Global Access (CGA) | 2. Opex including depreciation 4 One India1 : Building a Sustainable Legacy for Enduring Growth Highest-ever quarterly revenue of INR 3,516 Cr Branded Prescription Trade Generics Consumer Health ❖ Cipla maintained #2 rank in overall chronic segment2 ❖ Delivered a strong double-digit ❖ Anchor and transitioned brands ❖ Continued portfolio expansion with QoQ growth continuing to grow bigger recent launch of Yurpeak, Duolin Syncrobreathe, Revesmart and ❖ 3 Brands with TTM revenue of > ❖ Haircare delivered strong double- Rizontem INR 100 Cr and 5 Brands with TTM digit growth revenue of INR 50 Cr to INR 100 Cr ❖ Double-digit growth2 in chronic ❖ Omnigel, Nicotex, Prolyte and therapies like Respiratory, Cardiac, ❖ 18 new launches in Q2FY27 Cipladine maintained their Urology, Anti-diabetes, and leadership positions in the market Dermatology 1. One India includes Rx, Gx and CHL | 2. Market data as per IQVIA YTD Sep’26 India Rx : Strengthening Our Journey with Strategic Therapeutic Focus Steady Uptake in Key Therapies1 Growth (%) Rank Largest pharma company by volume (units) 1st in market2 Respiratory 11% Urology 11% Our in-house brand franchise, Dytor2, has scaled to over INR 800 Cr+ Anti-diabetic 50% 8th Cardiac 20% 7th Respiratory supremacy, with Cipla's brand franchises occupying all top 5 spots2 Dermatology 16% 11th Key Market Highlights 1000+ Cr Foracort 23 Brands 36 Brands 7 Therapies Biggest Respiratory IPM2 Brands in Top IPM2 Brands with With IPM2 Top 5 ranks Brand in IPM2 300 ranks revenue > INR 100 Cr 1. Market data as per IQVIA YTD Sep’26 | 2. Market data as per IQVIA MAT Sep’26 6 Recent Launches Demonstrate Strong Early Momentum Across Priority Therapies Respiratory Diabetology Cardiology Critical Care Galvus DM [ Vildagliptin SR+ Dytor E FDC Rizontem (Aztreonam and India’s first once-daily Dapagliflozin+ Metformin SR] is [Torsemide+Eplerenone] is Avibactam powder for nebulized bronchodilator for indicated for the treatment of indicated in the Patients with concentrate for solution for management of chronic patients with type 2 diabetes Congestive Heart Failure. Infusion) is indicated in obstructive pulmonary disease mellitus. treatment of complicated Urinary Tract Infection including pyelonephritis, Hospital-acquired Pneumonia including ventilator- associated pneumonia and Complicated intra- abdominal infection Disclaimer: Product images and descriptions are included for information purposes only and do not constitute promotional or advertising material. Please refer to the approved prescribing information/package insert for complete product details. 7 Strategic Alliances during the Quarter Bispecific HER2 ADC Pembrolizumab Biosimilar ❑ Exclusive licensing agreement with CTTQ ❑ Exclusive U.S. licensing and supply partnership (SinoBiopharma Group) for TQB2102 across with Qilu Pharmaceutical for QL2107, a India, South Africa and five other emerging Keytruda biosimilar. markets. ❑ Qilu will lead development, regulatory ❑ Advanced bispecific HER2 ADC with a registration and supply, while Cipla will be differentiated 3-in-1 mechanism and potential responsible for U.S. commercialization. safety/efficacy advantages. ❑ Strengthens Cipla’s oncology-focused ❑ Strengthens Cipla’s presence in ADCs and biosimilars portfolio and supports improved immunotherapy, targeting HER2-low breast access to advanced biologic therapies, subject cancer, ~50% of breast cancer cases [Showing first 8,000 characters — download PDF for full document]